SCHEMBL11891180

SCHEMBL11891180

CCCCN(CCCC)Cc1ccc2nc(Cc3cccs3)n(CCCN3CCCCC3)c2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MC4R P32245 4/20 0.45
▸ MC5R P33032 1/20 0.45
▸ MC3R P41968 1/20 0.45
▸ BCHE P06276 3/20 0.39
▸ ACHE P22303 3/20 0.39
▸ CNR2 P34972 2/20 0.39
▸ MEN1 O00255 1/20 0.37
▸ USP2 O75604 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ NPY1R P25929 1/20 0.37
▸ HRH3 Q9Y5N1 1/20 0.37
▸ NOS3 P29474 1/20 0.37
▸ NOS1 P29475 1/20 0.37
▸ OPRM1 P35372 1/20 0.37
▸ SIGMAR1 Q99720 1/20 0.36
▸ POLB P06746 2/20 0.36
▸ TSHR P16473 1/20 0.36
▸ LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11891166 0.90 MC4R (0.55) MC4RMC5RMC3R
SCHEMBL13124597 0.86 HTT (0.56) MC4RMEN1USP2KMT2AL3MBTL1
SCHEMBL11891183 0.83 MC4R (0.61) MC4RMC5RMC3RBCHEACHE
SCHEMBL11891182 0.82 MC4R (0.52) MC4RMC5RMC3RBCHEACHE
SCHEMBL11891184 0.77 MC4R (0.47) MC4RMC5RMC3RBCHEACHE
SCHEMBL13124434 0.76 MC4R (0.58) MC4RMC5RMC3RHTT
SCHEMBL11891126 0.76 MC4R (0.74) MC4RMC5RMC3R
SCHEMBL11891135 0.75 MC4R (0.64) MC4RMC5RMC3R
SCHEMBL13124561 0.74 MC4R (0.49) MC4RMC5RMC3R
SCHEMBL11891170 0.73 MC4R (0.73) MC4RMC5RMC3RBCHEACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120316201-A1 NOVEL BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AND USE THEREOF AS A MEDICAMENT IPSEN PHARMA S.A.S. (FR) 2012-12-13 — — US disclosed
US-20120316201-A1 NOVEL BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AND USE THEREOF AS A MEDICAMENT IPSEN PHARMA S.A.S. (FR) 2012-12-13 — — US disclosed
US-8227485-B2 Benzimidazole and imidazopyridine derivatives and use thereof as a medicament IPSEN PHARMA S.A.S. (FR) 2012-07-24 — — US disclosed
US-8227485-B2 Benzimidazole and imidazopyridine derivatives and use thereof as a medicament IPSEN PHARMA S.A.S. (FR) 2012-07-24 — — US disclosed
EP-1692114-B1 NOVEL BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AND USE THEREOF AS A MEDICAMENT IPSEN PHARMA (FR) 2010-09-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120316201-A1 NOVEL BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AND USE THEREOF AS A MEDICAMENT MC4R, MC5R, MC1R MC4R 1/4885MC5R 2/4885MC3R 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback